For the application of APOs in the treatment of thyroid cancer patients, a study shows that a high level of ApoA1 is related to a smaller size of PTC in a male cohort, especially in a subgroup aged less than 55-year-old, which suggests that ApoA1 has the potential to be a diagnostic indicator for PTC (Ma et al., 2021). This evidence concerns the gene APOA1 and thyroid gland carcinoma.